Tempest Therapeutics (TPST) investor relations material

Company overview and business model

• Clinical-stage biotechnology company with a portfolio of cell therapy and small molecule candidates targeting cancer and immunology indications.

• Expanded pipeline in February 2026 by acquiring dual-targeting CAR-T product candidates, including TPST-2003 for relapsed/refractory multiple myeloma.

• Small molecule candidate amezalpat (TPST-1120) completed Phase 2 in hepatocellular carcinoma and is Phase 3-ready; TPST-1495 to enter Phase 2 for familial adenomatous polyposis in 2026.

• Mission focuses on advancing clinical-stage candidates to address high unmet medical needs.

Financial performance and metrics

• Identified as a smaller reporting company and non-accelerated filer, with market value of public float under $700 million and annual revenue under $100 million.

• Audited financials for 2025 include a going concern qualification due to recurring losses and negative cash flows.

Use of proceeds and capital allocation

• Will not receive proceeds from selling stockholders' resale of shares; proceeds from warrant exercises (if any) will be used for working capital and general corporate purposes.

• Gross proceeds from full cash exercise of all warrants could total approximately $4.23 million.